000007800312/312023Q2false0.400000780032023-01-012023-07-020000078003us-gaap:CommonStockMember2023-01-012023-07-020000078003pfe:NotesDue20271.000Member2023-01-012023-07-0200000780032023-08-04xbrli:shares00000780032023-04-032023-07-02iso4217:USD00000780032022-04-042022-07-0300000780032022-01-012022-07-03iso4217:USDxbrli:shares00000780032023-07-0200000780032022-12-310000078003us-gaap:CommonStockMember2023-04-020000078003us-gaap:AdditionalPaidInCapitalMember2023-04-020000078003us-gaap:TreasuryStockCommonMember2023-04-020000078003us-gaap:RetainedEarningsMember2023-04-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-020000078003us-gaap:ParentMember2023-04-020000078003us-gaap:NoncontrollingInterestMember2023-04-0200000780032023-04-020000078003us-gaap:RetainedEarningsMember2023-04-032023-07-020000078003us-gaap:ParentMember2023-04-032023-07-020000078003us-gaap:NoncontrollingInterestMember2023-04-032023-07-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-04-032023-07-020000078003us-gaap:CommonStockMember2023-04-032023-07-020000078003us-gaap:AdditionalPaidInCapitalMember2023-04-032023-07-020000078003us-gaap:TreasuryStockCommonMember2023-04-032023-07-020000078003us-gaap:CommonStockMember2023-07-020000078003us-gaap:AdditionalPaidInCapitalMember2023-07-020000078003us-gaap:TreasuryStockCommonMember2023-07-020000078003us-gaap:RetainedEarningsMember2023-07-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-07-020000078003us-gaap:ParentMember2023-07-020000078003us-gaap:NoncontrollingInterestMember2023-07-020000078003us-gaap:CommonStockMember2022-04-030000078003us-gaap:AdditionalPaidInCapitalMember2022-04-030000078003us-gaap:TreasuryStockCommonMember2022-04-030000078003us-gaap:RetainedEarningsMember2022-04-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-030000078003us-gaap:ParentMember2022-04-030000078003us-gaap:NoncontrollingInterestMember2022-04-0300000780032022-04-030000078003us-gaap:RetainedEarningsMember2022-04-042022-07-030000078003us-gaap:ParentMember2022-04-042022-07-030000078003us-gaap:NoncontrollingInterestMember2022-04-042022-07-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-04-042022-07-030000078003us-gaap:CommonStockMember2022-04-042022-07-030000078003us-gaap:AdditionalPaidInCapitalMember2022-04-042022-07-030000078003us-gaap:TreasuryStockCommonMember2022-04-042022-07-030000078003us-gaap:CommonStockMember2022-07-030000078003us-gaap:AdditionalPaidInCapitalMember2022-07-030000078003us-gaap:TreasuryStockCommonMember2022-07-030000078003us-gaap:RetainedEarningsMember2022-07-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-07-030000078003us-gaap:ParentMember2022-07-030000078003us-gaap:NoncontrollingInterestMember2022-07-0300000780032022-07-030000078003us-gaap:CommonStockMember2022-12-310000078003us-gaap:AdditionalPaidInCapitalMember2022-12-310000078003us-gaap:TreasuryStockCommonMember2022-12-310000078003us-gaap:RetainedEarningsMember2022-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-12-310000078003us-gaap:ParentMember2022-12-310000078003us-gaap:NoncontrollingInterestMember2022-12-310000078003us-gaap:RetainedEarningsMember2023-01-012023-07-020000078003us-gaap:ParentMember2023-01-012023-07-020000078003us-gaap:NoncontrollingInterestMember2023-01-012023-07-020000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2023-01-012023-07-020000078003us-gaap:CommonStockMember2023-01-012023-07-020000078003us-gaap:AdditionalPaidInCapitalMember2023-01-012023-07-020000078003us-gaap:TreasuryStockCommonMember2023-01-012023-07-020000078003us-gaap:CommonStockMember2021-12-310000078003us-gaap:AdditionalPaidInCapitalMember2021-12-310000078003us-gaap:TreasuryStockCommonMember2021-12-310000078003us-gaap:RetainedEarningsMember2021-12-310000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2021-12-310000078003us-gaap:ParentMember2021-12-310000078003us-gaap:NoncontrollingInterestMember2021-12-3100000780032021-12-310000078003us-gaap:RetainedEarningsMember2022-01-012022-07-030000078003us-gaap:ParentMember2022-01-012022-07-030000078003us-gaap:NoncontrollingInterestMember2022-01-012022-07-030000078003us-gaap:AccumulatedOtherComprehensiveIncomeMember2022-01-012022-07-030000078003us-gaap:CommonStockMember2022-01-012022-07-030000078003us-gaap:AdditionalPaidInCapitalMember2022-01-012022-07-030000078003us-gaap:TreasuryStockCommonMember2022-01-012022-07-03pfe:operatingSegment0000078003pfe:SeagenMember2023-03-012023-03-310000078003pfe:SeagenMember2023-05-310000078003us-gaap:AccountsReceivableMember2023-07-020000078003us-gaap:AccountsReceivableMember2022-12-310000078003us-gaap:OtherCurrentLiabilitiesMember2023-07-020000078003us-gaap:OtherCurrentLiabilitiesMember2022-12-310000078003us-gaap:OtherNoncurrentLiabilitiesMember2023-07-020000078003us-gaap:OtherNoncurrentLiabilitiesMember2022-12-310000078003pfe:GBTMember2022-10-052022-10-050000078003pfe:GBTMember2022-10-050000078003pfe:GBTMemberus-gaap:InProcessResearchAndDevelopmentMember2022-10-050000078003pfe:GBTMemberus-gaap:DevelopedTechnologyRightsMember2022-10-050000078003pfe:GBTMemberus-gaap:DevelopedTechnologyRightsMember2022-10-052022-10-050000078003pfe:BiohavenMember2022-10-032022-10-030000078003pfe:BiohavenMember2022-10-030000078003us-gaap:DevelopedTechnologyRightsMemberpfe:BiohavenMember2022-10-030000078003us-gaap:DevelopedTechnologyRightsMemberpfe:BiohavenMember2022-10-032022-10-030000078003us-gaap:InProcessResearchAndDevelopmentMemberpfe:BiohavenMember2022-10-030000078003pfe:ArenaMember2022-03-112022-03-110000078003pfe:ArenaMember2022-03-110000078003us-gaap:InProcessResearchAndDevelopmentMemberpfe:ArenaMember2022-03-110000078003us-gaap:LicensingAgreementsMemberpfe:ArenaMember2022-03-110000078003pfe:ViatrisMember2023-07-020000078003pfe:ViatrisMember2022-12-310000078003pfe:HaleonMember2022-07-18xbrli:pure0000078003pfe:HaleonMember2023-07-020000078003pfe:HaleonMember2022-12-310000078003pfe:HaleonMember2023-01-012023-07-020000078003pfe:HaleonMember2023-04-032023-07-020000078003pfe:ConsumerHealthcareJVMember2022-04-042022-07-030000078003pfe:ConsumerHealthcareJVMember2022-01-012022-07-030000078003pfe:HaleonMember2023-01-012023-03-310000078003pfe:ConsumerHealthcareJVHaleonMember2022-01-012022-03-310000078003pfe:HaleonMember2022-10-012023-03-310000078003pfe:ConsumerHealthcareJVHaleonMember2021-10-012022-03-310000078003pfe:BlackstoneMember2023-04-012023-04-300000078003pfe:BlackstoneMember2023-04-032023-07-020000078003pfe:ClinicalTrialAgreementTermsMemberpfe:BlackstoneMember2023-04-300000078003pfe:NetSalesAndRoyaltyAgreementTermsMemberpfe:BlackstoneMember2023-04-300000078003pfe:FocusedCompanyPlanMember2023-07-020000078003pfe:FocusedCompanyPlanMemberpfe:BiopharmaSegmentMember2023-07-020000078003us-gaap:OtherNonoperatingIncomeExpenseMember2023-04-032023-07-020000078003us-gaap:OtherNonoperatingIncomeExpenseMember2022-04-042022-07-030000078003us-gaap:OtherNonoperatingIncomeExpenseMember2023-01-012023-07-020000078003us-gaap:OtherNonoperatingIncomeExpenseMember2022-01-012022-07-030000078003us-gaap:CostOfSalesMember2023-04-032023-07-020000078003us-gaap:CostOfSalesMember2022-04-042022-07-030000078003us-gaap:CostOfSalesMember2023-01-012023-07-020000078003us-gaap:CostOfSalesMember2022-01-012022-07-030000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-04-032023-07-020000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-04-042022-07-030000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2023-01-012023-07-020000078003us-gaap:SellingGeneralAndAdministrativeExpensesMember2022-01-012022-07-030000078003us-gaap:ResearchAndDevelopmentExpenseMember2023-04-032023-07-020000078003us-gaap:ResearchAndDevelopmentExpenseMember2022-04-042022-07-030000078003us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-07-020000078003us-gaap:ResearchAndDevelopmentExpenseMember2022-01-012022-07-030000078003pfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:RestructuringChargesAndAcquisitionRelatedCostsMemberpfe:ArenaMember2022-01-012022-04-030000078003us-gaap:EmployeeSeveranceMember2022-12-310000078003pfe:AssetImpairmentsMember2022-12-310000078003us-gaap:OtherRestructuringMember2022-12-310000078003us-gaap:EmployeeSeveranceMember2023-01-012023-07-020000078003pfe:AssetImpairmentsMember2023-01-012023-07-020000078003us-gaap:OtherRestructuringMember2023-01-012023-07-020000078003us-gaap:EmployeeSeveranceMember2023-07-020000078003pfe:AssetImpairmentsMember2023-07-020000078003us-gaap:OtherRestructuringMember2023-07-020000078003us-gaap:UnsecuredDebtMember2023-05-310000078003pfe:CerevelTherapeuticsLLCMember2023-04-032023-07-020000078003pfe:BioNTechMember2023-01-012023-07-020000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2022-04-042022-07-030000078003pfe:BioNTechAndCerevelTherapeuticsLLCMember2022-01-012022-07-030000078003us-gaap:CorporateNonSegmentMember2023-01-012023-07-020000078003us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:NimbusMember2023-01-012023-07-020000078003pfe:ViivHealthcareLimitedMember2023-01-012023-07-020000078003pfe:LicensingAgreementsAndOtherMember2023-07-020000078003us-gaap:FairValueInputsLevel1Memberpfe:LicensingAgreementsAndOtherMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberpfe:LicensingAgreementsAndOtherMember2023-07-020000078003pfe:LicensingAgreementsAndOtherMemberus-gaap:FairValueInputsLevel3Member2023-07-020000078003pfe:LicensingAgreementsAndOtherMember2023-01-012023-07-020000078003us-gaap:InProcessResearchAndDevelopmentMember2023-07-020000078003us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:FairValueInputsLevel1Member2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:InProcessResearchAndDevelopmentMember2023-07-020000078003us-gaap:InProcessResearchAndDevelopmentMemberus-gaap:FairValueInputsLevel3Member2023-07-020000078003us-gaap:InProcessResearchAndDevelopmentMember2023-01-012023-07-020000078003us-gaap:DevelopedTechnologyRightsMember2023-07-020000078003us-gaap:FairValueInputsLevel1Memberus-gaap:DevelopedTechnologyRightsMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:DevelopedTechnologyRightsMember2023-07-020000078003us-gaap:DevelopedTechnologyRightsMemberus-gaap:FairValueInputsLevel3Member2023-07-020000078003us-gaap:DevelopedTechnologyRightsMember2023-01-012023-07-020000078003us-gaap:FairValueInputsLevel1Member2023-07-020000078003us-gaap:FairValueInputsLevel2Member2023-07-020000078003us-gaap:FairValueInputsLevel3Member2023-07-020000078003us-gaap:AccumulatedTranslationAdjustmentMember2022-12-310000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2022-12-310000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2022-12-310000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2022-12-310000078003us-gaap:AccumulatedTranslationAdjustmentMember2023-01-012023-07-020000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-01-012023-07-020000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-01-012023-07-020000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-01-012023-07-020000078003us-gaap:AccumulatedTranslationAdjustmentMember2023-07-020000078003us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-020000078003us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember2023-07-020000078003us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:MoneyMarketFundsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:MoneyMarketFundsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:MoneyMarketFundsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:MoneyMarketFundsMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:MoneyMarketFundsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:ShortTermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Memberus-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMemberus-gaap:FairValueInputsLevel1Member2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ShortTermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:ForeignExchangeContractMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignExchangeContractMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Member2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel2Member2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberus-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:ForeignGovernmentDebtSecuritiesMemberpfe:LongtermInvestmentsMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberpfe:LongtermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberpfe:LongtermInvestmentsMemberus-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2023-07-020000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2023-07-020000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2022-12-310000078003us-gaap:FairValueMeasurementsRecurringMemberus-gaap:FairValueInputsLevel1Memberus-gaap:InterestRateContractMember2022-12-310000078003us-gaap:FairValueInputsLevel2Memberus-gaap:FairValueMeasurementsRecurringMemberus-gaap:InterestRateContractMember2022-12-310000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-07-020000078003us-gaap:CarryingReportedAmountFairValueDisclosureMember2022-12-310000078003us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2023-07-020000078003us-gaap:EstimateOfFairValueFairValueDisclosureMemberus-gaap:FairValueInputsLevel2Member2022-12-310000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2023-07-020000078003us-gaap:ForeignGovernmentDebtSecuritiesMember2022-12-310000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2023-07-020000078003us-gaap:USGovernmentAgenciesDebtSecuritiesMember2022-12-310000078003us-gaap:CorporateDebtSecuritiesMember2023-07-020000078003us-gaap:CorporateDebtSecuritiesMember2022-12-310000078003us-gaap:BankTimeDepositsMember2023-07-020000078003us-gaap:BankTimeDepositsMember2022-12-310000078003pfe:SeniorUnsecuredNotes4650DueMay2025Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredNotes4450DueMay2026Memberus-gaap:UnsecuredDebtMember2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredNotes4450DueMay2028Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredNotes4650DueMay2030Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredNotes4750DueMay2033Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredNotes5110DueMay2043Member2023-07-020000078003pfe:SeniorUnsecuredNotes5300DueMay2053Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredNotes5340DueMay2063Memberus-gaap:UnsecuredDebtMember2023-07-020000078003us-gaap:UnsecuredDebtMember2023-07-020000078003us-gaap:UnsecuredDebtMember2023-05-012023-05-3100000780032023-05-310000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue2024Member2022-12-310000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue2024Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue2025Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue2025Member2022-12-310000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue2026Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue2026Member2022-12-310000078003pfe:SeniorUnsecuredDebtDue2027Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredDebtDue2027Memberus-gaap:UnsecuredDebtMember2022-12-310000078003pfe:SeniorUnsecuredDebtDue2028Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredDebtDue2028Memberus-gaap:UnsecuredDebtMember2022-12-310000078003pfe:SeniorUnsecuredDebtDue2029Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredDebtDue2029Memberus-gaap:UnsecuredDebtMember2022-12-310000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue20302034Member2023-07-020000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue20302034Member2022-12-310000078003pfe:SeniorUnsecuredDebtDue20352039Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredDebtDue20352039Memberus-gaap:UnsecuredDebtMember2022-12-310000078003pfe:SeniorUnsecuredDebtDue20402044Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredDebtDue20402044Memberus-gaap:UnsecuredDebtMember2022-12-310000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue20452049Member2022-12-310000078003us-gaap:UnsecuredDebtMemberpfe:SeniorUnsecuredDebtDue20452049Member2023-07-020000078003pfe:SeniorUnsecuredDebtDue20502063Memberus-gaap:UnsecuredDebtMember2023-07-020000078003pfe:SeniorUnsecuredDebtDue20502063Memberus-gaap:UnsecuredDebtMember2022-12-310000078003us-gaap:UnsecuredDebtMember2022-12-310000078003us-gaap:ForeignExchangeContractMember2023-01-012023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMember2023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMember2022-12-310000078003us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-07-020000078003us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-12-310000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:SalesMemberus-gaap:ForeignExchangeContractMember2022-12-310000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2023-04-032023-07-020000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-04-042022-07-030000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-04-032023-07-020000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-04-042022-07-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2023-04-032023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2022-04-042022-07-030000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-04-032023-07-020000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-04-042022-07-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyDebtMember2023-04-032023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyDebtMember2022-04-042022-07-030000078003us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-04-032023-07-020000078003us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-04-042022-07-030000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2023-01-012023-07-020000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:InterestRateContractMember2022-01-012022-07-030000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-07-020000078003us-gaap:CashFlowHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-07-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2023-01-012023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:FairValueHedgingMemberus-gaap:InterestRateContractMember2022-01-012022-07-030000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2023-01-012023-07-020000078003us-gaap:NetInvestmentHedgingMemberus-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:ForeignExchangeContractMember2022-01-012022-07-030000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2023-01-012023-07-020000078003pfe:ForeignCurrencyShortTermBorrowingsMemberus-gaap:DesignatedAsHedgingInstrumentMember2022-01-012022-07-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyDebtMember2023-01-012023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberpfe:ForeignCurrencyDebtMember2022-01-012022-07-030000078003us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2023-01-012023-07-020000078003us-gaap:NondesignatedMemberus-gaap:ForeignExchangeContractMember2022-01-012022-07-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-04-032023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2023-01-012023-07-020000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-04-042022-07-030000078003us-gaap:DesignatedAsHedgingInstrumentMemberus-gaap:CostOfSalesMemberus-gaap:ForeignExchangeContractMember2022-01-012022-07-030000078003pfe:ForeignCurrencyDebtMember2023-07-020000078003pfe:ForeignCurrencyDebtMember2022-12-310000078003us-gaap:ShortTermDebtMember2023-07-020000078003us-gaap:ShortTermDebtMember2022-12-310000078003us-gaap:LongTermDebtMember2023-07-020000078003us-gaap:LongTermDebtMember2022-12-310000078003pfe:BioNTechMemberpfe:ComirnatyMemberus-gaap:CollaborativeArrangementMember2023-07-020000078003pfe:BioNTechMemberpfe:ComirnatyMemberus-gaap:CollaborativeArrangementMember2022-12-310000078003srt:MinimumMember2023-07-020000078003srt:MaximumMember2023-07-020000078003us-gaap:DevelopedTechnologyRightsMember2022-12-310000078003us-gaap:TradeNamesMember2023-07-020000078003us-gaap:TradeNamesMember2022-12-310000078003pfe:LicensingAgreementsAndOtherMember2022-12-310000078003us-gaap:TradeNamesMember2023-07-020000078003us-gaap:TradeNamesMember2022-12-310000078003us-gaap:InProcessResearchAndDevelopmentMember2022-12-310000078003pfe:LicensingAgreementsAndOtherMember2023-07-020000078003pfe:LicensingAgreementsAndOtherMember2022-12-310000078003pfe:ZavzpretMemberus-gaap:DevelopedTechnologyRightsMember2023-04-032023-07-020000078003pfe:ZavzpretMemberus-gaap:InProcessResearchAndDevelopmentMember2023-04-032023-07-020000078003pfe:NgenlaMemberus-gaap:DevelopedTechnologyRightsMember2023-04-032023-07-020000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-04-032023-07-020000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-04-042022-07-030000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-04-032023-07-020000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-04-042022-07-030000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-04-032023-07-020000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-04-042022-07-030000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2023-01-012023-07-020000078003us-gaap:PensionPlansDefinedBenefitMembercountry:US2022-01-012022-07-030000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2023-01-012023-07-020000078003us-gaap:PensionPlansDefinedBenefitMemberus-gaap:ForeignPlanMember2022-01-012022-07-030000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2023-01-012023-07-020000078003us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember2022-01-012022-07-030000078003pfe:EucrisaMemberpfe:PfizerVersusSeveralGenericManufacturersMemberus-gaap:PendingLitigationMemberpfe:PatentInfringementMember2021-09-012021-09-30pfe:patent0000078003pfe:PfizerVersusSeveralGenericManufacturersMemberus-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PatentInfringementMemberpfe:Expiring2030Member2022-08-012022-08-310000078003pfe:Expiring2033Memberpfe:PfizerVersusSeveralGenericManufacturersMemberus-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PatentInfringementMember2022-08-012022-08-310000078003pfe:PfizerVersusSeveralGenericManufacturersMemberus-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PatentInfringementMember2022-09-012022-09-300000078003pfe:PatentInvalidityAndNonInfringementMemberus-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PfizerVersusTevaPharmaceuticalsIncMemberpfe:TevaPharmaceuticalsIncMember2022-08-012022-08-310000078003us-gaap:PendingLitigationMemberpfe:MektoviMemberpfe:PfizerVersusTevaPharmaceuticalsIncMemberpfe:PatentInfringementMember2023-06-012023-06-300000078003pfe:ComirnatyMemberpfe:AlnylamPatentInfringementCaseMember2023-05-012023-05-310000078003pfe:ModernaTXUSPatentInfringementCaseMemberpfe:ComirnatyMember2022-08-012022-08-310000078003pfe:ComirnatyMemberpfe:ModernaTXEuropeanPatentInfringementCaseMember2022-08-012022-08-310000078003pfe:ComirnatyMemberpfe:ModernaTXEuropeanPatentInfringementCaseMember2022-09-012022-09-300000078003pfe:ArbutusAndGenevantUSPatentInfringementCaseMemberpfe:ComirnatyMember2023-04-012023-04-300000078003pfe:AbrysvoMemberus-gaap:SubsequentEventMemberpfe:GlaxoSmithKlineBiologicsSAAndGlaxoSmithKlineLLCUSPatentInfringementCaseMember2023-08-012023-08-090000078003pfe:ComirnatyMemberpfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember2022-07-012022-07-310000078003pfe:ComirnatyMemberpfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacJudgmentOfNonInfringementMember2023-05-012023-05-310000078003pfe:PfizerBioNTechAndBioNTechManufacturingGmbHVersusCureVacAdditionalPatentInfringementAssertionMemberpfe:ComirnatyMember2023-05-012023-05-310000078003pfe:DocetaxelMemberpfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMemberus-gaap:PendingLitigationMember2018-01-012018-12-31pfe:manufacturer0000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003us-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003us-gaap:CorporateNonSegmentMember2023-04-032023-07-020000078003us-gaap:CorporateNonSegmentMember2022-04-042022-07-030000078003us-gaap:CorporateNonSegmentMember2022-01-012022-07-030000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2023-04-032023-07-020000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2022-04-042022-07-030000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2023-01-012023-07-020000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAmortizationOfIntangibleAssetsMember2022-01-012022-07-030000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2023-04-032023-07-020000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2022-04-042022-07-030000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2023-01-012023-07-020000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsAcquisitionRelatedCostsMember2022-01-012022-07-030000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2023-04-032023-07-020000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2022-04-042022-07-030000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2023-01-012023-07-020000078003us-gaap:MaterialReconcilingItemsMemberpfe:ReconcilingItemsOtherMember2022-01-012022-07-030000078003pfe:ViivHealthcareLimitedMember2023-04-032023-07-020000078003pfe:ViivHealthcareLimitedMember2022-04-042022-07-030000078003pfe:ViivHealthcareLimitedMember2022-01-012022-07-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:CorporateNonSegmentMember2022-04-042022-07-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:CorporateNonSegmentMember2022-01-012022-07-030000078003srt:RevisionOfPriorPeriodReclassificationAdjustmentMemberus-gaap:OperatingSegmentsMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003country:US2023-04-032023-07-020000078003country:US2022-04-042022-07-030000078003country:US2023-01-012023-07-020000078003country:US2022-01-012022-07-030000078003pfe:DevelopedEuropeMember2023-04-032023-07-020000078003pfe:DevelopedEuropeMember2022-04-042022-07-030000078003pfe:DevelopedEuropeMember2023-01-012023-07-020000078003pfe:DevelopedEuropeMember2022-01-012022-07-030000078003pfe:DevelopedRestOfWorldMember2023-04-032023-07-020000078003pfe:DevelopedRestOfWorldMember2022-04-042022-07-030000078003pfe:DevelopedRestOfWorldMember2023-01-012023-07-020000078003pfe:DevelopedRestOfWorldMember2022-01-012022-07-030000078003pfe:EmergingMarketsMember2023-04-032023-07-020000078003pfe:EmergingMarketsMember2022-04-042022-07-030000078003pfe:EmergingMarketsMember2023-01-012023-07-020000078003pfe:EmergingMarketsMember2022-01-012022-07-030000078003pfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-04-032023-07-020000078003pfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2023-01-012023-07-020000078003pfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-04-042022-07-030000078003pfe:GovernmentAndGovernmentSponsoredMemberus-gaap:CustomerConcentrationRiskMemberus-gaap:SalesRevenueNetMember2022-01-012022-07-030000078003us-gaap:CreditConcentrationRiskMemberpfe:GovernmentAndGovernmentSponsoredMemberus-gaap:AccountsReceivableMember2022-01-012022-12-310000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:ComirnatyMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:PaxlovidMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:EliquisMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:PrevnarPrevenarFamilyMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:NurtecODTVyduraMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:NurtecODTVyduraMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:NurtecODTVyduraMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:BiopharmaSegmentMemberpfe:NurtecODTVyduraMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:PremarinFamilyMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:BMP2Memberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:BMP2Memberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:BMP2Memberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:BMP2Memberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:FSMEIMMUNTicoVacMemberpfe:PrimaryCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:NimenrixMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:PrimaryCareMemberpfe:OtherPrimaryCareProductsMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:VyndaqelMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:VyndaqelMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:VyndaqelMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:VyndaqelMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:XeljanzMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:SulperazonMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:SulperazonMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:SulperazonMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:SulperazonMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:EnbrelMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:IgPortfolioProductsMember2022-01-012022-07-030000078003pfe:InflectraMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:InflectraMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:InflectraMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:InflectraMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:ZaviceftaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:ZaviceftaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:ZaviceftaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:ZaviceftaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:GenotropinMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:GenotropinMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:GenotropinMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:GenotropinMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BeneFIXMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:ZithromaxZmaxMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:ZithromaxZmaxMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:ZithromaxZmaxMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:ZithromaxZmaxMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:MedrolMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:MedrolMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:MedrolMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:MedrolMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:OxbrytaMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:OxbrytaMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:OxbrytaMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:OxbrytaMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:SomavertMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:SomavertMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:SomavertMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:SomavertMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:FragminMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:FragminMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:FragminMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:FragminMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:ReFactoAfXynthaMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:VfendMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:VfendMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:VfendMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:VfendMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:CresembaMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:CresembaMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:CresembaMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:CresembaMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:BicillinMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:BicillinMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:BicillinMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:BicillinMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:CibinqoMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:CibinqoMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:CibinqoMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:BiopharmaSegmentMemberpfe:CibinqoMember2022-01-012022-07-030000078003pfe:SpecialtyCareMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:SpecialtyCareMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:SpecialtyCareMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:SpecialtyCareMemberpfe:OtherAntiinfectivesMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:OtherSpecialtyCareMemberpfe:SpecialtyCareMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:IbranceMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XtandiAllianceRevenuesMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XtandiAllianceRevenuesMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XtandiAllianceRevenuesMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XtandiAllianceRevenuesMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:InlytaMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:BosulifMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:BosulifMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:BosulifMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:BosulifMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:ZirabevMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:ZirabevMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:ZirabevMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:ZirabevMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:LorbrenaMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:RuxienceMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:XalkoriMember2022-01-012022-07-030000078003pfe:RetacritMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:RetacritMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:RetacritMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:RetacritMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:BavencioAllianceRevenuesMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:BavencioAllianceRevenuesMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:BavencioAllianceRevenuesMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:BavencioAllianceRevenuesMemberpfe:OncologyMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:AromasinMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BesponsaMemberpfe:BiopharmaSegmentMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BesponsaMemberpfe:BiopharmaSegmentMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BesponsaMemberpfe:BiopharmaSegmentMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BesponsaMemberpfe:BiopharmaSegmentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:BraftoviMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:SutentMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:MektoviMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:TrazimeraMember2022-01-012022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2023-04-032023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2022-04-042022-07-030000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2023-01-012023-07-020000078003pfe:OncologyMemberpfe:BiopharmaSegmentMemberpfe:OtherOncologyProductsMember2022-01-012022-07-030000078003pfe:BusinessInnovationSegmentMember2023-04-032023-07-020000078003pfe:BusinessInnovationSegmentMember2022-04-042022-07-030000078003pfe:BusinessInnovationSegmentMember2023-01-012023-07-020000078003pfe:BusinessInnovationSegmentMember2022-01-012022-07-030000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMember2023-04-032023-07-020000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMember2022-04-042022-07-030000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMember2023-01-012023-07-020000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMember2022-01-012022-07-030000078003pfe:BusinessInnovationSegmentMemberpfe:PfizerIgniteMember2023-04-032023-07-020000078003pfe:BusinessInnovationSegmentMemberpfe:PfizerIgniteMember2022-04-042022-07-030000078003pfe:BusinessInnovationSegmentMemberpfe:PfizerIgniteMember2023-01-012023-07-020000078003pfe:BusinessInnovationSegmentMemberpfe:PfizerIgniteMember2022-01-012022-07-030000078003pfe:TotalAllianceBiopharmaceuticalsMember2023-04-032023-07-020000078003pfe:TotalAllianceBiopharmaceuticalsMember2022-04-042022-07-030000078003pfe:TotalAllianceBiopharmaceuticalsMember2023-01-012023-07-020000078003pfe:TotalAllianceBiopharmaceuticalsMember2022-01-012022-07-030000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMemberpfe:BioNTechMember2023-04-032023-07-020000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMemberpfe:BioNTechMember2023-01-012023-07-020000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMemberpfe:BioNTechMember2022-04-042022-07-030000078003pfe:PfizerCentreOneMemberpfe:BusinessInnovationSegmentMemberpfe:BioNTechMember2022-01-012022-07-030000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyMember2023-07-020000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyMember2022-12-310000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyMember2023-04-032023-07-020000078003pfe:GovernmentAndGovernmentSponsoredMemberpfe:ComirnatyMember2023-01-012023-07-020000078003us-gaap:CreditConcentrationRiskMemberpfe:GovernmentAndGovernmentSponsoredMemberus-gaap:AccountsReceivableMember2023-01-012023-07-02

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 10-Q

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended July 2, 2023

OR

TRANSITION REPORT PURSUANT TO SECTION 13
OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _______ to _______


COMMISSION FILE NUMBER 1-3619

----

PFIZER INC.
(Exact name of registrant as specified in its charter)
Delaware13-5315170
(State of Incorporation)(I.R.S. Employer Identification No.)

66 Hudson Boulevard East, New York, New York  10001-2192
(Address of principal executive offices)  (zip code)
(212) 733-2323
(Registrant’s telephone number including area code)
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.05 par valuePFENew York Stock Exchange
1.000% Notes due 2027PFE27New York Stock Exchange
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
YesxNo

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
YesxNo

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act:

Large Accelerated filer x              Accelerated filer                 Non-accelerated filer            Smaller reporting company      Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).
YesNo
x

At August 4, 2023, 5,645,959,570 shares of the issuer’s voting common stock were outstanding.



TABLE OF CONTENTS
Page
 
 
Item 2.
 
 
 
 
 
 
Item 3. 
Defaults Upon Senior SecuritiesN/A
Item 4. 
Mine Safety DisclosuresN/A
Item 5. 
Other Information
 
N/A = Not Applicable
2


DEFINED TERMS

Unless the context requires otherwise, references to “Pfizer,” “the Company,” “we,” “us” or “our” in this Form 10-Q (defined below) refer to Pfizer Inc. and its subsidiaries. Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 28, 2023 and May 29, 2022, and for U.S. subsidiaries is as of and for the three and six months ended July 2, 2023 and July 3, 2022. References to “Notes” in this Form 10-Q are to the Notes to the Condensed or Consolidated Financial Statements in this Form 10-Q or in our 2022 Form 10-K. We also have used several other terms in this Form 10-Q, most of which are explained or defined below:
2022 Form 10-K
Annual Report on Form 10-K for the fiscal year ended December 31, 2022
AlexionAlexion Pharma International Operations Limited
ALKanaplastic lymphoma kinase
Alliance revenuesRevenues from alliance agreements under which we co-promote products discovered or developed by other companies or us
ArenaArena Pharmaceuticals, Inc.
AstellasAstellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.
ATTR-CMtransthyretin amyloid cardiomyopathy
BiohavenBiohaven Pharmaceutical Holding Company Ltd.
BioNTechBioNTech SE
BiopharmaGlobal Biopharmaceuticals Business
BlackstoneBlackstone Life Sciences
BMSBristol-Myers Squibb Company
BODBoard of Directors
CDCU.S. Centers for Disease Control and Prevention
CMA
conditional marketing authorisation
Comirnaty*
Unless otherwise noted, refers to, as applicable, and as authorized or approved, the Pfizer-BioNTech COVID-19 Vaccine, the Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5), the Comirnaty Original/Omicron BA.1 Vaccine, and Comirnaty Original/Omicron BA.4/BA.5 Vaccine. In the U.S., the original monovalent mRNA COVID-19 vaccine is no longer emergency use authorized or CDC-recommended, although Comirnaty remains a licensed vaccine.
Cond. J-NDA Conditional Japan New Drug Application
Consumer Healthcare JVGSK Consumer Healthcare JV
COVID-19novel coronavirus disease of 2019
Developed Europe
Includes the following markets: Western Europe, Scandinavian countries and Finland
Developed MarketsIncludes the following markets: U.S., Developed Europe, Japan, Australia, Canada, South Korea and New Zealand
Developed Rest of World
Includes the following markets: Japan, Australia, Canada, South Korea and New Zealand
ECEuropean Commission
EMAEuropean Medicines Agency
Emerging Markets
Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Central Europe, the Middle East, Africa and Turkey
EPSearnings per share
ESG
Environmental, Social and Governance
EUEuropean Union
EUAemergency use authorization
Exchange ActSecurities Exchange Act of 1934, as amended
FASBFinancial Accounting Standards Board
FDAU.S. Food and Drug Administration
FFDCAU.S. Federal Food, Drug and Cosmetic Act
Form 10-QThis Quarterly Report on Form 10-Q for the quarterly period ended July 2, 2023
GAAPGenerally Accepted Accounting Principles
GBTGlobal Blood Therapeutics, Inc.
GPDGlobal Product Development
GSKGSK plc
HaleonHaleon plc
HIPAAHealth Insurance Portability and Accountability Act of 1996
HospiraHospira, Inc.
IPR&Din-process research and development
IRAInflation Reduction Act of 2022
IRSU.S. Internal Revenue Service
JAKJanus kinase
JVjoint venture
KingKing Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)
LIBORLondon Interbank Offered Rate
LOEloss of exclusivity
3


mCRCmetastatic colorectal cancer
mCRPC
metastatic castration-resistant prostate cancer
mCSPC
metastatic castration-sensitive prostate cancer
MD&AManagement’s Discussion and Analysis of Financial Condition and Results of Operations
MDLMulti-District Litigation
MeridianMeridian Medical Technologies, Inc.
Moody’sMoody’s Investors Service
mRNAmessenger ribonucleic acid
MSAManufacturing Supply Agreement
MylanMylan N.V.
NDANew Drug Application
Nimbus
Nimbus Therapeutics, LLC
nmCRPC
non-metastatic castration-resistant prostate cancer
NSCLCnon-small cell lung cancer
ODToral disintegrating tablet
OnoOno Pharmaceutical Co., Ltd.
OPKOOPKO Health, Inc.
OTCover-the-counter
Paxlovid*an oral COVID-19 treatment (nirmatrelvir [PF-07321332] tablets and ritonavir tablets)
PC1Pfizer CentreOne
PharmaciaPharmacia LLC (formerly Pharmacia Corporation)
PIE
Pfizer Investment Enterprises Pte. Ltd. (a wholly-owned finance subsidiary of Pfizer)
Prevnar familyIncludes Prevnar 13/Prevenar 13 (pediatric and adult) and Prevnar 20/Apexxnar (pediatric and adult)
PsApsoriatic arthritis
QTDQuarter-to-date or three months ended
RArheumatoid arthritis
RCCrenal cell carcinoma
R&Dresearch and development
S&PStandard & Poor’s
SeagenSeagen Inc.
SECU.S. Securities and Exchange Commission
SI&Aselling, informational and administrative
TSAstransition service arrangements
UCulcerative colitis
U.K.United Kingdom
U.S.United States
Upjohn BusinessPfizer’s former global, primarily off-patent branded and generics business, which included a portfolio of 20 globally recognized solid oral dose brands, including Lipitor, Lyrica, Norvasc, Celebrex and Viagra, as well as a U.S.-based generics platform, Greenstone, that was spun-off on November 16, 2020 and combined with Mylan to create Viatris
ViatrisViatris Inc.
ViiVViiV Healthcare Limited
Vyndaqel familyIncludes Vyndaqel, Vyndamax and Vynmac
WRDMWorldwide Research, Development and Medical
YTD
Year-to-date or six months ended
*The Pfizer-BioNTech COVID-19 Vaccine, Bivalent (Original and Omicron BA.4/BA.5) and certain uses of Paxlovid have not been approved or licensed by the FDA. The Pfizer-BioNTech COVID-19 Vaccine, Bivalent has been authorized by the FDA under an EUA to prevent COVID-19 in individuals aged 6 months and older. Paxlovid has been authorized for emergency use by the FDA under an EUA for the treatment of mild-to-moderate COVID-19 in pediatric patients (12 years of age and older weighing at least 40 kg) who are at high risk for progression to severe COVID-19, including hospitalization or death. The emergency uses are only authorized for the duration of the declaration that circumstances exist justifying the authorization of emergency use of the medical product during the COVID-19 pandemic under Section 564(b)(1) of the FFDCA unless the declaration is terminated or authorization revoked sooner. Please see the EUA Fact Sheets at www.covid19oralrx.com and www.cvdvaccine-us.com.
This Form 10-Q includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.
Some amounts in this Form 10-Q may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks mentioned are the property of their owners.
The information contained on our website, our Facebook, Instagram, YouTube and LinkedIn pages or our Twitter accounts, or any third-party website, is not incorporated by reference into this Form 10-Q.
4


PART I.  FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF INCOME
(UNAUDITED)
 Three Months EndedSix Months Ended
(MILLIONS, EXCEPT PER SHARE DATA)July 2,
2023
July 3,
2022
July 2,
2023
July 3,
2022
Revenues$12,734 $27,742 $31,015 $53,402 
Costs and expenses:
Cost of sales(a)
3,237 8,648 8,122 18,632 
Selling, informational and administrative expenses(a)
3,497 3,048 6,914 5,642 
Research and development expenses(a)
2,648 2,815 5,153 5,116 
Acquired in-process research and development expenses33 1 55 356 
Amortization of intangible assets1,184 822 2,287 1,657 
Restructuring charges and certain acquisition-related costs214 189 222 381 
Other (income)/deductions––net(347)772 (277)1,122 
Income from continuing operations before provision/(benefit) for taxes on income2,269 11,447 8,539 20,497 
Provision/(benefit) for taxes on income(71)1,570 644 2,742 
Income from continuing operations2,340 9,877 7,895 17,756 
Discontinued operations––net of tax(2)34 (1)26 
Net income before allocation to noncontrolling interests2,338 9,911 7,894 17,781 
Less: Net income attributable to noncontrolling interests11 6 24 12 
Net income attributable to Pfizer Inc. common shareholders$2,327 $9,906 $7,870 $17,769 
Earnings per common share––basic:
    
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.41 $1.76 $1.40 $3.17 
Discontinued operations––net of tax 0.01   
Net income attributable to Pfizer Inc. common shareholders$0.41 $1.77 $1.40 $3.17 
Earnings per common share––diluted:
    
Income from continuing operations attributable to Pfizer Inc. common shareholders$0.41 $1.73 $1.38 $3.09 
Discontinued operations––net of tax 0.01   
Net income attributable to Pfizer Inc. common shareholders$0.41 $1.73 $1.38 $3.10 
Weighted-average shares––basic5,646 5,593 5,640 5,605 
Weighted-average shares––diluted5,713 5,712 5,720 5,735 
(a)Exclusive of amortization of intangible assets.
See Accompanying Notes.
5


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(UNAUDITED)
 Three Months EndedSix Months Ended
(MILLIONS)July 2,
2023
July 3,
2022
July 2,
2023
July 3,
2022
Net income before allocation to noncontrolling interests$2,338 $9,911 $7,894 $17,781 
Foreign currency translation adjustments, net242 (1,268)343 (1,631)
Unrealized holding gains/(losses) on derivative financial instruments, net109 651 112 854 
Reclassification adjustments for (gains)/losses included in net income(a)
(163)(144)140 (357)
 (54)507 251 497 
Unrealized holding gains/(losses) on available-for-sale securities, net26 (486)113 (620)
Reclassification adjustments for (gains)/losses included in net income(b)
16 255 (493)487 
 42 (232)(379)(132)
Reclassification adjustments related to amortization of prior service costs and other, net(30)(31)(59)(68)
Reclassification adjustments related to curtailments of prior service costs and other, net(7)1 (12)(10)
 (37)(30)(72)(78)
Other comprehensive income/(loss), before tax193 (1,023)143 (1,344)
Tax provision/(benefit) on other comprehensive income/(loss)9 (55)(53)(115)
Other comprehensive income/(loss) before allocation to noncontrolling interests$184 $(968)$196 $(1,228)
Comprehensive income/(loss) before allocation to noncontrolling interests$2,522 $8,943 $8,091 $16,553 
Less: Comprehensive income/(loss) attributable to noncontrolling interests8  18 6 
Comprehensive income/(loss) attributable to Pfizer Inc.$2,514 $8,943 $8,072 $16,546 
(a)Reclassified into Other (income)/deductions—net and Cost of sales. See Note 7E.
(b)Reclassified into Other (income)/deductions—net.
See Accompanying Notes.
6


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED BALANCE SHEETS
(MILLIONS)July 2,
2023
December 31, 2022
(Unaudited)
Assets
Cash and cash equivalents$2,632 $416 
Short-term investments42,153 22,316 
Trade accounts receivable, less allowance for doubtful accounts: 2023—$471; 2022—$449
10,231 10,952 
Inventories10,310 8,981 
Current tax assets3,194 3,577 
Other current assets4,828 5,017 
Total current assets73,347 51,259 
Equity-method investments11,422 11,033 
Long-term investments3,644 4,036 
Property, plant and equipment, less accumulated depreciation: 2023—$15,554; 2022—$15,174
17,488 16,274 
Identifiable intangible assets41,406 43,370 
Goodwill51,572 51,375 
Noncurrent deferred tax assets and other noncurrent tax assets8,261 6,693 
Other noncurrent assets13,028 13,163 
Total assets$220,168 $197,205 
Liabilities and Equity  
Short-term borrowings, including current portion of long-term debt: 2023—$3,565; 2022—$2,560
$3,985 $2,945 
Trade accounts payable6,081 6,809 
Dividends payable2,315 2,303 
Income taxes payable2,928 1,587 
Accrued compensation and related items1,972 3,407 
Deferred revenues1,286 2,520 
Other current liabilities16,079 22,568 
Total current liabilities34,647 42,138 
Long-term debt61,356 32,884 
Pension and postretirement benefit obligations2,184 2,250 
Noncurrent deferred tax liabilities1,232 1,023 
Other taxes payable8,052 9,812 
Other noncurrent liabilities13,403 13,180 
Total liabilities120,875 101,288 
Commitments and Contingencies
Common stock478 476 
Additional paid-in capital92,329 91,802 
Treasury stock(114,482)(113,969)
Retained earnings128,796 125,656 
Accumulated other comprehensive loss(8,102)(8,304)
Total Pfizer Inc. shareholders’ equity99,019 95,661 
Equity attributable to noncontrolling interests274 256 
Total equity99,293 95,916 
Total liabilities and equity$220,168 $197,205 
See Accompanying Notes.
7


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF EQUITY
(UNAUDITED)
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd’l
Paid-In Capital
SharesCostRetained EarningsAccum. Other Comp.
Loss
Share-
holders’ Equity
Non-controlling interestsTotal Equity
Balance, April 2, 2023
9,560 $478 $92,153 (3,915)$(114,473)$131,101 $(8,289)$100,970 $266 $101,236 
Net income2,327 2,327 11 2,338 
Other comprehensive income/(loss), net of tax
187 187 (3)184 
Cash dividends declared, per share: $0.82
Common stock(4,630)(4,630)(4,630)
Share-based payment transactions1 — 176 — (8)(4)164 164 
Other— — — — — —  
Balance, July 2, 2023
9,561 $478 $92,329 (3,916)$(114,482)$128,796 $(8,102)$99,019 $274 $99,293 
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd’l
Paid-In Capital
SharesCostRetained EarningsAccum. Other Comp.
Loss
Share-
holders’ Equity
Non-controlling interestsTotal Equity
Balance, April 3, 2022
9,494 $476 $90,844 (3,903)$(113,931)$111,193 $(6,157)$82,424 $261 $82,685 
Net income9,906 9,906 6 9,911 
Other comprehensive income/(loss), net of tax(963)(963)(5)(968)
Cash dividends declared, per share: $0.80
Common stock (4,489)(4,489)(4,489)
Share-based payment transactions2 — 339 — (8)(2)330 330 
Other— — — — — —  
Balance, July 3, 2022
9,496 $476 $91,183 (3,903)$(113,939)$116,608 $(7,119)$87,208 $261 $87,469 
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd’l
Paid-In Capital
SharesCostRetained EarningsAccum. Other Comp.
Loss
Share-
holders’ Equity
Non-controlling interestsTotal Equity
Balance, January 1, 2023
9,519 $476 $91,802 (3,903)$(113,969)$125,656 $(8,304)$95,661 $256 $95,916 
Net income7,870 7,870 24 7,894 
Other comprehensive income/(loss), net of tax202 202 (6)196 
Cash dividends declared, per share: $0.82
Common stock(4,630)(4,630)(4,630)
Share-based payment transactions42 2 527 (12)(512)(101)(85)(85)
Other— — — — — —  
Balance, July 2, 2023
9,561 $478 $92,329 (3,916)$(114,482)$128,796 $(8,102)$99,019 $274 $99,293 
PFIZER INC. SHAREHOLDERS
Common StockTreasury Stock
(MILLIONS, EXCEPT PER SHARE DATA)SharesPar ValueAdd’l
Paid-In Capital
SharesCostRetained EarningsAccum. Other Comp.
Loss
Share-
holders’ Equity
Non-controlling interestsTotal Equity
Balance, January 1, 2022
9,471 $473 $90,591 (3,851)$(111,361)$103,394 $(5,897)$77,201 $262 $77,462 
Net income17,769 17,769 12 17,781 
Other comprehensive income/(loss), net of tax(1,223)(1,223)(6)(1,228)
Cash dividends declared, per share: $0.80
Common stock (4,489)(4,489)(4,489)
Share-based payment transactions25 2 588 (12)(578)(66)(53)(53)
Purchases of common stock(39)(2,000)(2,000)(2,000)
Other3 — — — 3 (7)(4)
Balance, July 3, 20229,496 $476 $91,183 (3,903)$(113,939)$116,608 $(7,119)$87,208 $261 $87,469 
See Accompanying Notes.
8


PFIZER INC. AND SUBSIDIARY COMPANIES
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(UNAUDITED)
 Six Months Ended
(MILLIONS)July 2,
2023
July 3,
2022
Operating Activities  
Net income before allocation to noncontrolling interests$7,894 $17,781 
Discontinued operations—net of tax(1)26 
Net income from continuing operations before allocation to noncontrolling interests7,895 17,756 
Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by/(used in) operating activities:  
Depreciation and amortization3,060 2,362 
Asset write-offs and impairments327 58 
Deferred taxes(1,471)(3,461)
Share-based compensation expense253 373 
Benefit plan contributions in excess of expense/income(322)(146)
Other adjustments, net(317)1,270 
Other changes in assets and liabilities, net of acquisitions and divestitures(9,423)(3,496)
Net cash provided by/(used in) operating activities from continuing operations4 14,717 
Net cash provided by/(used in) operating activities from discontinued operations (5)
Net cash provided by/(used in) operating activities4 14,711 
Investing Activities  
Purchases of property, plant and equipment(2,053)(1,394)
Purchases of short-term investments(21,006)(18,937)
Proceeds from redemptions/sales of short-term investments12,594 20,151 
Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less(11,217)(3,153)
Purchases of long-term investments(92)(1,324)
Proceeds from redemptions/sales of long-term investments172 226 
Acquisitions of businesses, net of cash acquired(25)(6,225)
Other investing activities, net(543)(91)
Net cash provided by/(used in) investing activities(22,170)(10,746)
Financing Activities  
Proceeds from short-term borrowings14 4,012 
Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less
22 379 
Proceeds from issuance of long-term debt30,831  
Payments on long-term debt(1,269)(1,609)
Purchases of common stock (2,000)
Cash dividends paid(4,618)(4,493)
Other financing activities, net(576)(347)
Net cash provided by/(used in) financing activities24,403 (4,058)
Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents
(7)(67)
Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents2,229 (159)
Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period468 1,983 
Cash and cash equivalents and restricted cash and cash equivalents, at end of period$2,698 $1,824 
Supplemental Cash Flow Information
Cash paid/(received) during the period for:  
Income taxes
$2,025 $3,098 
Interest paid
821 771 
Interest rate hedges31 (10)
See Accompanying Notes.
9


PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)

Note 1. Basis of Presentation and Significant Accounting Policies
A. Basis of Presentation
We prepared these condensed consolidated financial statements in conformity with U.S. GAAP, consistent in all material respects with those applied in our 2022 Form 10-K. As permitted under the SEC requirements for interim reporting, certain footnotes or other financial information have been condensed or omitted.
These financial statements include all normal and recurring adjustments that are considered necessary for the fair statement of results for the interim periods presented. The information included in this Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our 2022 Form 10-K. Revenues, expenses, assets and liabilities can vary during each quarter of the year. Therefore, the results and trends in these interim financial statements may not be representative of those for the full year.
Pfizer’s fiscal quarter-end for subsidiaries operating outside the U.S. is as of and for the three and six months ended May 28, 2023 and May 29, 2022, and for U.S. subsidiaries is as of and for the three and six months ended July 2, 2023 and July 3, 2022.
We manage our commercial operations through two operating segments, each led by a single manager: Biopharma and Business Innovation. Biopharma is the only reportable segment. See Note 13A below and Note 17A in our 2022 Form 10-K.
Business development activities impacted financial results in the periods presented. In March 2023, we and Seagen announced that the companies entered into an agreement under which we will acquire Seagen, a global biotechnology company that discovers, develops and commercializes transformative cancer medicines, for $229 in cash per Seagen share for a total enterprise value of approximately $43 billion. We expect to finance the transaction substantially through $31 billion of long-term debt issued in May 2023 (see Note 7D), and the balance from a combination of short-term financing and existing cash. The transaction was approved by Seagen’s shareholders in May 2023. The transaction is expected to close in late 2023 or early 2024, and remains subject to customary closing conditions, including receipt of required regulatory approvals. See Note 2 below, as well as Notes 1A and 2 in our 2022 Form 10-K.
We have made certain reclassification adjustments to conform prior-period amounts to the current presentation for segment reporting.
B. New Accounting Standards Adopted in 2023
On January 1, 2023, we adopted a new accounting standard for supplier finance programs which requires increased disclosures in the notes to our financial statements. See Note 8C.
In the second quarter of 2023, we adopted new accounting standards on reference rate reform that provide temporary optional expedients and exceptions to the guidance for contracts, hedging relationships, and other transactions that reference LIBOR or another reference rate that were discontinued after June 30, 2023. We applied certain of the optional expedients related to hedge accounting relationships. The main purpose of the expedients is to allow hedge accounting to continue uninterrupted and make it easier to apply the requirements to maintain hedge accounting during the transition period through December 31, 2024.
C. Revenues and Trade Accounts Receivable
Customers––Our prescription biopharmaceutical products, with the exception of Paxlovid, are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies. We principally sell Paxlovid to government agencies and distributors. In the U.S., we primarily sell our vaccines directly to the federal government (including the CDC), wholesalers, individual provider offices, retail pharmacies and integrated delivery systems. Outside the U.S., we primarily sell our vaccines to government and non-government institutions.
Deductions from Revenues––Our accruals for Medicare, Medicaid and related state program and performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts are as follows:
(MILLIONS)July 2,
2023
December 31, 2022
Reserve against Trade accounts receivable, less allowance for doubtful accounts
$1,236 $1,200 
Other current liabilities:
Accrued rebates4,868 4,479 
Other accruals412 430 
Other noncurrent liabilities
473 612 
Total accrued rebates and other sales-related accruals$6,989 $6,722 
10


PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Trade Accounts Receivable––Trade accounts receivable are stated at their net realizable value. The allowance for credit losses reflects our best estimate of expected credit losses of the receivables portfolio determined on the basis of historical experience, current information, and forecasts of future economic conditions. In developing the estimate for expected credit losses, trade accounts receivables are segmented into pools of assets depending on market (U.S. versus international), delinquency status, and customer type (high risk versus low risk and government versus non-government), and fixed reserve percentages are established for each pool of trade accounts receivables.
In determining the reserve percentages for each pool of trade accounts receivables, we considered our historical experience with certain customers and customer types, regulatory and legal environments, country and political risk, and other relevant current and future forecasted macroeconomic factors. When management becomes aware of certain customer-specific factors that impact credit risk, specific allowances for these known troubled accounts are recorded.
During the three and six months ended July 2, 2023 and July 3, 2022, additions to the allowance for credit losses, write-offs and recoveries of customer receivables were not material to our condensed consolidated financial statements. For additional information on our trade accounts receivable, see Note 1G in our 2022 Form 10-K.
Note 2. Acquisitions, Discontinued Operations, Equity-Method Investment and Research and Development Arrangement
A. Acquisitions
GBT––On October 5, 2022, we acquired GBT, a biopharmaceutical company dedicated to the discovery, development and delivery of life-changing treatments for underserved patient communities, starting with sickle cell disease. The total fair value of the consideration transferred was $5.7 billion ($5.2 billion, net of cash acquired). In connection with this business combination, we provisionally recorded: (i) $4.4 billion in Identifiable intangible assets, consisting of $3.0 billion of IPR&D and $1.4 billion of developed technology rights with a useful life of six years, (ii) $1.1 billion of Goodwill, (iii) $672 million of inventories to be sold over approximately three years, (iv) $568 million of net deferred tax liabilities and (v) $331 million of assumed long-term debt that was paid in full in the fourth quarter of 2022. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
Biohaven––On October 3, 2022, we acquired Biohaven, the maker of Nurtec ODT/Vydura (rimegepant), an innovative therapy approved for both acute treatment of migraine and prevention of episodic migraine in adults. The total fair value of the consideration transferred was $11.8 billion, which includes the fair value of Pfizer’s previous investment in Biohaven on the acquisition date of approximately $300 million. In connection with this business combination, we provisionally recorded: (i) $12.1 billion in Identifiable intangible assets, consisting of $11.6 billion of developed technology rights with a useful life of 11 years and $450 million of IPR&D, (ii) $813 million of inventories to be sold over approximately two years, (iii) $795 million of Goodwill, (iv) $398 million of trade accounts receivable, (v) $1.4 billion of assumed long-term debt that was paid in full in the fourth quarter of 2022, (vi) $566 million of net deferred tax liabilities and (vii) $476 million of Other current liabilities. The allocation of the consideration transferred to the assets acquired and liabilities assumed has not yet been finalized.
Arena––On March 11, 2022, we acquired Arena, a clinical stage company with development-stage therapeutic candidates in gastroenterology, dermatology and cardiology. The total fair value of the consideration transferred was $6.6 billion ($6.2 billion, net of cash acquired). The final allocation of the consideration transferred to the assets acquired and the liabilities assumed was completed in the first quarter of 2023. In connection with this business combination, we recorded: (i) $5.5 billion in Identifiable intangible assets, consisting of $5.0 billion of IPR&D and $460 million of indefinite-lived licensing agreements and other, (ii) $1.0 billion of Goodwill and (iii) $490 million of net deferred tax liabilities.
B. Discontinued Operations
Discontinued operations––net of tax in the periods presented relate to post-close adjustments for previously divested businesses. In the three and six months ended July 2, 2023 and July 3, 2022, amounts recorded under interim agreements, including TSAs and MSAs, associated with these disposals were not material. Under agreements related to the 2020 spin-off and the combination of the Upjohn Business with Mylan to form Viatris, net amounts due to Viatris were $25 million as of July 2, 2023 and $94 million as of December 31, 2022. The cash flows associated with the agreements are included in Net cash provided by/(used in) operating activities. For information about the nature of these agreements, see Note 2B in our 2022 Form 10-K.
C. Equity-Method Investment
Haleon/Consumer Healthcare JV––On July 18, 2022, GSK completed a demerger of the Consumer Healthcare JV which became Haleon, an independent, publicly traded company listed on the London Stock Exchange that holds the joint historical
11


PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
consumer healthcare business of GSK and Pfizer following the demerger. We continue to own 32% of the ordinary shares of Haleon after the demerger.
The carrying value of our investment in Haleon as of July 2, 2023 and as of December 31, 2022 is $11.2 billion and $10.8 billion, respectively, and is reported in Equity-method investments. The fair value of our investment in Haleon as of July 2, 2023, based on quoted market prices of Haleon stock, was $12.1 billion. Haleon/the Consumer Healthcare JV is a foreign investee whose reporting currency is the U.K. pound, and therefore we translate its financial statements into U.S. dollars and recognize the impact of foreign currency translation adjustments in the carrying value of our investment and in other comprehensive income. The increase in the value of our investment from December 31, 2022 is primarily due to $271 million in pre-tax foreign currency translation adjustments (see Note 6) and our share of Haleon’s earnings of $219 million, partially offset by $88 million in dividends received. We record our share of earnings from Haleon/the Consumer Healthcare JV on a quarterly basis on a one-quarter lag in Other (income)/deductions––net. Our total share of Haleon’s earnings generated in the first quarter of 2023, which we recorded in our operating results in the second quarter of 2023, was $151 million. Our total share of Haleon’s earnings generated in the fourth quarter of 2022 and first quarter of 2023, which we recorded in our operating results in the first six months of 2023, was $219 million. Our total share of the JV’s earnings generated in the first quarter of 2022, which we recorded in our operating results in the second quarter of 2022, was $150 million. Our total share of the JV’s earnings generated in the fourth quarter of 2021 and first quarter of 2022, which we recorded in our operating results in the first six months of 2022, was $335 million. The total amortization and adjustment of basis differences resulting from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of Haleon/the Consumer Healthcare JV is included in Other (income)/deductions—net and was not material to our results of operations in the periods presented. See Note 4.
Summarized financial information for our equity-method investee, Haleon/the Consumer Healthcare JV, for the three and six months ending March 31, 2023, the most recent period available, and for the three and six months ending March 31, 2022, is as follows:
Three Months EndedSix Months Ended
(MILLIONS)March 31,
2023
March 31,
2022
March 31,
2023
March 31,
2022
Net sales$3,627 $3,526 $6,889 $6,945 
Cost of sales(1,392)(1,322)(2,888)(2,634)
Gross profit$2,235 $2,204 $4,001 $4,312 
Income from continuing operations504 487 730 1,077 
Net income504 487 730 1,077 
Income attributable to shareholders473 468 684 1,046 
D. Research and Development Arrangement
Research and Development Funding Arrangement with Blackstone––In April 2023, we entered into an arrangement with Blackstone under which we will receive up to a total of $550 million in 2023 through 2026 to co-fund our quarterly development costs for specified treatments. As there is substantive transfer of risk to the financial partner, the development funding is recognized by us as an obligation to perform contractual services. We are recognizing the funding as a reduction of Research and development expenses using an attribution model over the period of the related expenses. The reduction to Research and development expenses for the second quarter of 2023 was $45 million. If successful, upon regulatory approval in the U.S. or certain major markets in the EU for the indications based on the applicable clinical trials, Blackstone will be eligible to receive approval-based fixed milestone payments of up to $468 million contingent upon the successful results of the clinical trials. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product. Following potential regulatory approval, Blackstone will be eligible to receive a combination of fixed milestone payments of up to $550 million in total based on achievement of certain levels of cumulative applicable net sales, as well as royalties based on a mid-to-high single digit percentage of the applicable net sales. Fixed sales-based milestone payments will be recorded as intangible assets and amortized to Amortization of intangible assets over the shorter of the term of the agreement or estimated commercial life of the product, and royalties on net sales will be recorded as Cost of sales when incurred.
12


PFIZER INC. AND SUBSIDIARY COMPANIES.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives
A. Transforming to a More Focused Company Program
In 2019, we announced that we would be incurring costs associated with our Transforming to a More Focused Company Program, a multi-year effort to ensure our cost base aligns appropriately with our operating structure following Pfizer’s transformation into a more focused, innovative science-based global biopharmaceutical business. This program includes activities to (i) restructure our corporate enabling functions to appropriately support our operating structure; (ii) transform our commercial go-to-market model; and (iii) optimize our manufacturing network and R&D operations.
The activities associated with transforming our commercial go-to-market model are substantially complete. Activities associated with restructuring our corporate enabling functions and optimizing our manufacturing network and R&D operations are ongoing and are expected to be substantially completed by the end of 2023. The costs to restructure our corporate enabling functions, and to optimize our R&D operations and reduce cycle times, as well as to further prioritize our internal R&D portfolio, primarily include severance and implementation costs. The costs to optimize our manufacturing network largely include severance, implementation costs, product transfer costs, site exit costs, and accelerated depreciation.
From the start of this program in the fourth quarter of 2019 through July 2, 2023, we incurred costs of $3.8 billion, of which $1.5 billion ($1.1 billion of restructuring charges) is associated with Biopharma. We have incurred approximately 85% of total expected costs to date, and we expect the remaining costs to be substantially incurred through 2023.
B. Key Activities
The following summarizes costs and credits for acquisitions and cost-reduction/productivity initiatives:
Three Months EndedSix Months Ended
(MILLIONS)July 2,
2023
July 3,
2022
July 2,
2023
July 3,
2022
Restructuring charges/(credits):    
Employee terminations$96 $110